Investigational Drug Information for Setipiprant
✉ Email this page to a colleague
What is the drug development status for Setipiprant?
Setipiprant is an investigational drug.
There have been 4 clinical trials for Setipiprant.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2011.
The most common disease conditions in clinical trials are Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, and Rhinitis. The leading clinical trial sponsors are Actelion, Idorsia Pharmaceuticals Ltd., and Allergan.
Summary for Setipiprant
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 31 |
| WIPO Patent Applications | 25 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 3 (2011-12-01) |
| Vendors | 49 |
Recent Clinical Trials for Setipiprant
| Title | Sponsor | Phase |
|---|---|---|
| A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males | Allergan | Phase 2 |
| Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis | Actelion | Phase 3 |
| Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis | Idorsia Pharmaceuticals Ltd. | Phase 3 |
Clinical Trial Summary for Setipiprant
Top disease conditions for Setipiprant
Top clinical trial sponsors for Setipiprant
US Patents for Setipiprant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
